Related Experiment Videos
Incidentalomas--clinical correlation and translational science required
1Johns Hopkins University School of Medicine, Baltimore, USA.
The New England Journal of Medicine
|June 30, 2006
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Obexelimab for the Treatment of IgG4-Related Disease.
The New England journal of medicine·2026
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.
The New England journal of medicine·2026
Secukinumab for Giant Cell Arteritis.
NEJM evidence·2026
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease.
Annals of the rheumatic diseases·2026
Evaluation of steroid toxicity using the Glucocorticoid Toxicity Index-Metabolic Domains instrument in adults with myasthenia gravis: a real-world study in the USA.
Journal of comparative effectiveness research·2026
Fibromyalgia.
The New England journal of medicine·2026
Health Care-Associated Infections in U.S. Hospitals, 2023 versus 2015.
The New England journal of medicine·2026
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
The New England journal of medicine·2026
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
The New England journal of medicine·2026
Andes Virus - A Clinical Review.
The New England journal of medicine·2026
Platelet-Activating Anti-Platelet Factor 4 Disorders.
The New England journal of medicine·2026
US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study.
Future oncology (London, England)·2026
Epitranscriptomic control of epithelial-mesenchymal transition in cancer: mechanisms, plasticity, and therapeutic opportunities.
Frontiers in cell and developmental biology·2026
A cross-validated deep learning framework for automated detection of DMBA-induced ovarian cancer from histopathological images with CA-125 biomarker support.
Frontiers in artificial intelligence·2026